Saghmos Therapeutics is a privately held biopharmaceuticals company with a Phase 3-ready cardiorenal metabolic modulator ST-62516 (trimetazidine). Saghmos’ IND for ST-62516 was cleared by the FDA in July 2023. ST-62516 is being developed to reduce the risk of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) after contrast procedures such as percutaneous coronary intervention (PCI). This is an area of high unmet need. Patients with pre-existing Chronic Kidney Disease (CKD) and comorbidities such as diabetes and heart disease are at high risk of complications, including heart failure and progression of kidney disease, leading to prolonged hospitalization and need for dialysis. There are no approved pharmacologic agents to prevent or treat the problem. Saghmos Therapeutics has an issued US patent providing exclusivity through 2037 for the prevention and treatment of acute kidney injury after contrast procedures.
Greenwich, Connecticut, US
Saghmos Therapeutics reposted this
Thank you to the panel on the important conversation on #healthequity and #patientcentricity Ramona Sequeira TAKEDA PHARMACEUTICALS AMERICA, INC., Gavin MacBeath TScan Therapeutics, Anna Kazanchyan, M.D. Sanghmos Therapeutics, Deborah C. Mash DemeRx, & Sharon (Mandler) Suchotliff, MPH ZS
Thank you, Jacob Gottlieb and Altium Capital for bringing focus on the need for integrated therapeutic approaches that combine cardiovascular and kidney care.
Recent research highlights a stronger-than-ever connection between cardiovascular and kidney health. Shared risk factors like obesity, diabetes, and metabolic dysfunction drive the progression of both Cardiovascular Disease (CVD) and Chronic Kidney Disease (CKD), contributing to what the American Heart Association calls Cardiovascular-Kidney-Metabolic (CKM) Syndrome. According to a May 8, 2024, research letter in JAMA, 90% of U.S. adults already have at least stage one CKM syndrome, underscoring the urgent need for integrated treatments. Recent Breakthroughs in Treatment: → EMPA-KIDNEY Trial: The drug empagliflozin, initially developed for diabetes, has shown significant promise in slowing CKD progression while reducing cardiovascular-related deaths and hospitalizations (NEJM, Vol. 388 No. 2). → Finerenone: This promising drug has significantly reduced all-cause mortality and hospitalization risks for patients with CKD and heart failure (European Society of Cardiology, 2024, September 1). Key Opportunities 📌 Inflammation & Blood Pressure Control: Chronic inflammation and high blood pressure accelerate heart and kidney damage. Anti-inflammatory therapies and advanced blood pressure medications present strong growth potential for investors. Look for companies focused on reducing oxidative stress and improving vascular health. 📌 Biomarker-Based Early Detection: Early detection is crucial for managing both CVD and CKD. Innovative companies developing biomarker-driven diagnostics are poised to lead the next wave of breakthroughs, improving disease prediction and prevention. These findings emphasize the need for integrated therapeutic approaches that combine cardiovascular and kidney care. Investors and healthcare professionals alike should stay updated on these developments, as managing CVD and CKD together can lead to more effective treatments and better long-term health outcomes for patients. #CardiovascularHealth #KidneyHealth #HealthcareInnovation #MedicalResearch #BiotechBreakthroughs #HealthTech #ClinicalTrials #HealthcareInvestment
Saghmos Therapeutics reposted this
Join me and Stephen Grant MD, Former Deputy Director, FDA, Division of Cardiology and Nephrology and currently Saghmos’ Chief Regulatory Officer, at the UBS 2024 Biotechnology Private Company Virtual Symposium on Wednesday, September 18th at 10:30am Eastern Time. We will be discussing our Phase 3-ready cardiovascular-kidney metabolic asset, ST-62516, aimed at reducing the risk of cardiorenal complications after PCI. A live webcast of the session can be accessed at https://lnkd.in/eap8Kzeb. Stay tuned for a replay of the webcast available shortly after the presentation. https://lnkd.in/e87ESQwr #phase3 #cardiorenal #CKM #acutekidneyinjury
Saghmos Therapeutics reposted this
Please join me and Stephen Grant MD, Former Deputy Director, FDA, Division of Cardiology and Nephrology and currently our Chief Regulatory Officer, at the Morgan Stanley 22nd Annual Global Healthcare Conference, on Wednesday, September 4th at 2:35 pm Eastern Time to learn more about our Phase 3-ready cardiovascular-kidney metabolic asset, ST-62516, for reducing the risk of cardiorenal complications after PCI. We will host 1-on-1 meetings September 4-6th at the conference; you can reach us via Morgan Stanley conference platform or LinkedIn message. The presentation will be webcast live at: https://lnkd.in/e6mxQ8jm, with a replay available shortly thereafter. https://lnkd.in/ezHaEMWJ #phase3 #cardiorenal #CKM #acutekidneyinjury
Saghmos Therapeutics reposted this
We are excited to announce Saghmos Therapeutics' participation at the Morgan Stanley 22nd Annual Global Healthcare Conference, to be held at the New York Marriott Marquis. Please join me and Stephen Grant MD, Former Deputy Director, FDA, Division of Cardiology and Nephrology and currently our Chief Regulatory Officer, on Wednesday, September 4th at 2:35 pm Eastern Time to learn more about our Phase 3-ready cardiovascular-kidney metabolic asset, ST-62516, for reducing the risk of cardiorenal complications after PCI. We will host 1-on-1 meetings September 4-6th at the conference; you can reach us via Morgan Stanley conference platform or LinkedIn message. The presentation will be webcast live at: https://lnkd.in/e6mxQ8jm, with a replay available shortly thereafter.
Saghmos Therapeutics reposted this
Saghmos Therapeutics is participating in the 3rd Annual Kidney Virtual Conference hosted by H.C. Wainwright. Please join me on Monday, July 15, 2024 at 11 a.m. ET via live webcast (https://lnkd.in/ez5GFpX6) to learn more about our Phase 3-ready cardiovascular-kidney-metabolic modular, ST-62516. Saghmos is developing ST-62516 for reducing the risk of complications after PCI, a major unmet medical need with no FDA-approved drugs and a multi-billion dollar revenue potential. Stephen Grant, M.D., former Deputy Director of FDA’s Division of Cardiology and Nephrology and Saghmos’ Chief Regulatory Officer and I will be available for 1x1 virtual meetings. Reach out via LinkedIn message to schedule a meeting. A replay of the webcast will be available shortly after the presentation. #CKM #CardiovascularKidneyMetabolic #Cardiorenal #AcuteKidneyInjury #AKI #PCI #CVRM #ChronicKidneyDisease #CKD #Dialysis
Saghmos Therapeutics reposted this
Our 3rd Annual Kidney Conference will take place virtually on July 15th. Join us for a day of insightful panel discussions to stay informed on developments in the kidney space, company 1x1 meetings, and hear updates from the following participating companies: Akebia Therapeutics, Aurinia Pharmaceuticals Inc., CalciMedica, Kezar Life Sciences, POXEL, Regulus Therapeutics, Rockwell Medical, Inc., Saghmos Therapeutics, Travere Therapeutics, Unicycive Therapeutics, Vera Therapeutics, Inc., Walden Biosciences, and ZyVersa Therapeutics Inc. For more information and to register, visit: https://lnkd.in/eJeRyQHW
Saghmos Therapeutics reposted this
Productive discussion on managing the runway with #biotech CEOs Paul Peter Tak, MD PhD FMedSci Candel Tx, Anna Kazanchyan, M.D. Saghmos Therapeutics, Dror Harats ImmuneWalk Therapeutics, Brendan Smith Doppler Bio & Pratik Shah Design Therapeutics #longwoodhealthcareleaders
Saghmos Therapeutics reposted this
Excited to announced the issuance of the second U.S patent for our Phase 3-ready cardiorenal-metabolic modulator ST-62516. The patent provides for exclusivity through 2037, with broad claims for the reduction of Acute Kidney Injury (AKI) and Major Adverse Cardiac and Kidney Events (MACKE) in patients with Cardiovascular-Kidney-Metabolic (CKM) Syndrome Undergoing Procedures with contrast dyes. #CKM #cardiorenal #AKI #PCI
Saghmos Therapeutics reposted this
We are excited to announce Saghmos Therapeutics' participation at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL. Please join me on June 12th at 3:20pm ET to learn more about our Phase 3-ready cardio-renal asset, ST-62516 (trimetazidine) for reducing the risk of cardiorenal complications after PCI. Dr. Stephen Grant, former Deputy Director of the FDA's Division of Cardiology and Nephrology and currently our Chief Regulatory Officer, and I will be available for 1x1 meetings June 10-12th - please get in touch via LinkedIn message, if interested. The presentation will be webcast live at: https://lnkd.in/eQFHBkhj, with a replay available shortly thereafter. https://lnkd.in/epzrwCpw